Sangamo Therapeutics Inc

SGMO

Equity

ISIN null / Valor 1066659

NASDAQ (2025-11-21)

USD 0.42+9.97%

Sangamo Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Sangamo Therapeutics Inc is a genomic medicine company focused on developing innovative treatments for severe diseases with limited treatment options. The company's mission is to utilize cutting-edge science to create transformative therapies that improve the lives of patients. Sangamo aims to address unmet medical needs and provide hope for individuals suffering from debilitating conditions.

Summarized from source with an LLMView SourceSector:

Release Schedule

The company will release its Q3 2025 financial results before the market opens on November 6, 2025, and will host a conference call at 8:30 a.m. Eastern time.

Conference Call Details

The earnings call is open to the public, with participants able to join either by dialing in with a unique passcode or through a dial-out option. Registration is required, and joining early is recommended.

Webcast and Replay

The call can also be accessed via a live webcast on the Sangamo Therapeutics website, with a replay available for those who are unable to attend live.

Summarized from source with an LLMView Source

Key figures

-78.4%1Y

-88.2%3Y

-95.9%5Y

Performance

130%1Y

124%3Y

106%5Y

Volatility